Source author record

Jina Park

Jina Park appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Applications

Catalog footprint

What is connected

2works

1topics

4close collaborators

Actions

Connect this record

Open graph Browse works

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

preprint2025arXiv

Analysis of Log Data from an International Online Educational Assessment System: A Multi-state Survival Modeling Approach to Reaction Time between and across Action Sequence

With increasingly available computer-based or online assessments, researchers have shown keen interest in analyzing log data to improve our understanding of test takers' problem-solving processes. In this paper, we propose a multi-state survival model (MSM) to action sequence data from log files, focusing on modeling test takers' reaction times between actions, in order to investigate which factors and how they influence test takers' transition speed between actions. We specifically identify the key actions that differentiate correct and incorrect answers, compare transition probabilities between these groups, and analyze their distinct problem-solving patterns. Through simulation studies and sensitivity analyses, we evaluate the robustness of our proposed model. We demonstrate the proposed approach using problem-solving items from the Programme for the International Assessment of Adult Competencies (PIAAC).

preprint2022arXiv

A Bayesian Precision Response-adaptive Phase II Clinical Trial Design for Radiotherapies with Competing Risk Survival Outcomes

Many phase II clinical trials have used survival outcomes as the primary endpoints in recent decades. Suppose the radiotherapy is evaluated in a phase II trial using survival outcomes. In that case, the competing risk issue often arises because the time to disease progression can be censored by the time to normal tissue complications, and vice versa. Besides, much literature has examined that patients receiving the same radiotherapy dose may yield distinct responses due to their heterogeneous radiation susceptibility statuses. Therefore, the "one-dose-fit-all" strategy often fails, and it is more relevant to evaluate the subgroup-specific treatment effect with the subgroup defined by the radiation susceptibility status. In this paper, we propose a Bayesian precision phase II trial design evaluating the subgroup-specific treatment effects of radiotherapy. We use the cause-specific hazard approach to model the competing risk survival outcomes. We propose restricting the candidate radiation doses based on each patient's radiation susceptibility status. Only the clinically feasible personalized dose will be considered, which enhances the benefit for the patients in the trial. In addition, we propose a stratified Bayesian adaptive randomization scheme such that more patients will be randomized to the dose reporting more favorable survival outcomes. Numerical studies have shown that the proposed design performed well and outperformed the conventional design ignoring the competing risk issue.